论文部分内容阅读
含克拉维酸复合制剂的开发是克服病原菌对β_内酰胺类抗生素耐药和提高感染性疾病抗菌疗法疗效的重要途径.
The development of the composite formulation with clavulanic acid is an important way to overcome the antibacterial effect of the pathogen on β-lactam antibiotics and improve the anti-bacterial therapy of infectious diseases.